Naloxone Accord (Naloxone Hydrochloride)

Naloxone is an opioid antagonist used in the management of opioid overdose and related respiratory depression.

• Opioid overdose: provides rapid reversal of life‑threatening respiratory depression, restoring adequate breathing and consciousness in emergency situations.
• Opioid‑induced respiratory depression: counteracts central nervous system depression caused by opioid agonists, normalizing ventilation and oxygenation.
• Acute opioid toxicity: antagonizes μ‑opioid receptors to mitigate sedation, miosis and hypotension associated with toxic opioid exposure.
• Pre‑hospital emergency care: enables first responders to stabilize patients before transport to definitive care.

• Naloxone acts as a competitive antagonist at opioid receptors, especially the μ‑opioid subtype. By binding to these receptors with higher affinity than opioid agonists, it displaces the agonist molecules and blocks further activation, rapidly terminating opioid‑mediated effects such as analgesia, respiratory depression, and sedation. The antagonistic action is dose‑dependent and reversible, allowing restoration of normal neuronal activity in the brainstem respiratory centers.

Naloxone may be associated with several adverse reactions following intramuscular or intravenous administration.

Common Side Effects

• Injection site pain: mild discomfort or soreness at the injection site.
• Nausea: transient feeling of queasiness.
• Vomiting: occasional emesis after administration.
• Sweating: increased perspiration.
• Tremor: mild shaking of limbs.

Serious or Rare Side Effects

• Acute pulmonary edema: sudden fluid accumulation in lungs.
• Cardiac arrhythmias: irregular heart rhythm.
• Seizures: convulsive episodes.
• Anaphylaxis: severe allergic reaction with airway compromise.

When using Naloxone, several precautions should be observed to ensure safe and effective administration.

• Verify overdose: confirm signs of opioid overdose before administration.
• Assess airway: ensure airway patency and breathing status prior to dosing.
• Monitor vital signs: observe blood pressure, heart rate and respiration after injection.
• Adjust for cardiovascular disease: use cautiously in patients with known heart conditions.
• Consider chronic opioid therapy: anticipate possible withdrawal symptoms in dependent individuals.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Naloxone can interact with other medications, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Combined use with potent vasopressors: may cause severe hypertension.
• Concurrent opioid antagonists: may reduce analgesic effect of needed opioids.
• High‑dose catecholamines: risk of cardiovascular instability.

Moderate Interactions (Monitor Closely)

• Benzodiazepines: enhanced sedation and respiratory depression risk.
• Tricyclic antidepressants: increased likelihood of seizures.
• Other emergency drugs (e.g., epinephrine): monitor hemodynamic response.